Literature DB >> 29475930

Primary Gastric EBV-positive Diffuse Large B Cell Lymphoma (DLBCL) of the Elderly with Plasmablastic Differentiation.

Ming Hu1, Jose Trevino2, Lijun Yang1, Dengfeng Cao3, Xiuli Liu1, Jinping Lai4.   

Abstract

Epstein-Barr virus (EBV)-positive diffuse large B cell lymphoma (DLBCL) of the elderly is a rare subtype of B-cell neoplasms. Primary gastric EBV-positive DLBCL of the elderly with partial plasmablastic phenotype is extremely rare. Differentiation of EBV-positive DLBCL of the elderly with partial plasmablastic phenotype from true plasmablastic lymphoma (PBL) is difficult and very important from the therapeutic and prognostic point of view. Here we report a case of a 59-year-old man with upper gastrointestinal bleeding. The esophagogastroduodenoscopy revealed a 2-cm malignant-appearing non-bleeding gastric ulcer in the gastric cardia. Biopsy showed ulcerated tissue with atypical lymphoid cell infiltrate, morphologically consistent with immunoblasts. The atypical large cells were positive for CD20, PAX5, MUM-1, and a subset of large cells was positive for CD30, BCL6 and CD138. Ki-67 proliferation index exceeded 90% of the tumor cells. In situ hybridization (ISH) for EBV-encoded RNAs (EBERs) was extensively positive. Kappa/Lambda ISH showed lambda restriction. The final diagnosis was primary gastric EBV-positive DLBCL of the elderly with plasmablastic phenotype. The patient finished 5 cycles of R-DA-EPOCH with significant clinical improvement. To the best of our knowledge, this is an extremely rare case of primary gastric EBV-positive DLBCL of the elderly with plasmablastic phenotype. Copyright
© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Stomach; diffuse large B cell Lymphoma; in situ hybridization; ommunohistochemistry; plasmablastic lymphoma

Mesh:

Substances:

Year:  2018        PMID: 29475930      PMCID: PMC5905215          DOI: 10.21873/invivo.11255

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  11 in total

Review 1.  CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.

Authors:  Jorge J Castillo; Julio C Chavez; Francisco J Hernandez-Ilizaliturri; Santiago Montes-Moreno
Journal:  Expert Rev Hematol       Date:  2015-02-01       Impact factor: 2.929

2.  CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

Authors:  Michael Pfreundschuh; Evelyn Kuhnt; Lorenz Trümper; Anders Osterborg; Marek Trneny; Lois Shepherd; Devinder S Gill; Jan Walewski; Ruth Pettengell; Ulrich Jaeger; Pier-Luigi Zinzani; Ofer Shpilberg; Stein Kvaloy; Peter de Nully Brown; Rolf Stahel; Noel Milpied; Armando López-Guillermo; Viola Poeschel; Sandra Grass; Markus Loeffler; Niels Murawski
Journal:  Lancet Oncol       Date:  2011-09-21       Impact factor: 41.316

Review 3.  The 2016 revision of the World Health Organization classification of lymphoid neoplasms.

Authors:  Steven H Swerdlow; Elias Campo; Stefano A Pileri; Nancy Lee Harris; Harald Stein; Reiner Siebert; Ranjana Advani; Michele Ghielmini; Gilles A Salles; Andrew D Zelenetz; Elaine S Jaffe
Journal:  Blood       Date:  2016-03-15       Impact factor: 22.113

4.  IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas.

Authors:  Alexandra Valera; Olga Balagué; Luis Colomo; Antonio Martínez; Jan Delabie; Lekidelu Taddesse-Heath; Elaine S Jaffe; Elías Campo
Journal:  Am J Surg Pathol       Date:  2010-11       Impact factor: 6.394

5.  Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype.

Authors:  Santiago Montes-Moreno; Ana-Rosa Gonzalez-Medina; Socorro-María Rodriguez-Pinilla; Lorena Maestre; Lydia Sanchez-Verde; Giovanna Roncador; Manuela Mollejo; Juan F García; Javier Menarguez; Carlos Montalbán; M Carmen Ruiz-Marcellan; Eulogio Conde; Miguel A Piris
Journal:  Haematologica       Date:  2010-04-23       Impact factor: 9.941

6.  Expression pattern of XBP1(S) in human B-cell lymphomas.

Authors:  Lorena Maestre; Reuben Tooze; Marta Cañamero; Santiago Montes-Moreno; Rocio Ramos; Gina Doody; May Boll; Sharon Barrans; Sara Baena; Miguel Angel Piris; Giovanna Roncador
Journal:  Haematologica       Date:  2009-01-27       Impact factor: 9.941

7.  Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.

Authors:  Chi Young Ok; Ling Li; Zijun Y Xu-Monette; Carlo Visco; Alexander Tzankov; Ganiraju C Manyam; Santiago Montes-Moreno; Karen Dybkaer; Karen Dybaer; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Jiayu Chen; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Weiyun Ai; Maurilio Ponzoni; Andrés J M Ferreri; John P Farnen; Michael B Møller; Carlo E Bueso-Ramos; Roberto N Miranda; Jane N Winter; Miguel A Piris; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

8.  PRDM1/BLIMP-1 expression in multiple B and T-cell lymphoma.

Authors:  José-Francisco Garcia; Giovanna Roncador; Juan-Fernando García; Ana-Isabel Sánz; Lorena Maestre; Elena Lucas; Santiago Montes-Moreno; Rebeca Fernandez Victoria; Jorge L Martinez-Torrecuadrara; Teresa Marafioti; David Y Mason; Miguel A Piris
Journal:  Haematologica       Date:  2006-04       Impact factor: 9.941

Review 9.  EBV-positive diffuse large B-cell lymphoma of the elderly: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Jorge J Castillo; Brady E Beltran; Roberto N Miranda; Ken H Young; Julio C Chavez; Eduardo M Sotomayor
Journal:  Am J Hematol       Date:  2016-05       Impact factor: 10.047

10.  Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.

Authors:  Ting-Xun Lu; Jin-Hua Liang; Yi Miao; Lei Fan; Li Wang; Xiao-Yan Qu; Lei Cao; Qi-Xing Gong; Zhen Wang; Zhi-Hong Zhang; Wei Xu; Jian-Yong Li
Journal:  Sci Rep       Date:  2015-07-23       Impact factor: 4.379

View more
  2 in total

1.  CircCFL1/MiR-107 Axis Targeting HMGB1 Promotes the Malignant Progression of Diffuse Large B-Cell Lymphoma Tumors.

Authors:  Xiaowei Chen; Xiaobin Xie; Wei Zhou
Journal:  Cancer Manag Res       Date:  2020-09-30       Impact factor: 3.989

2.  Laryngeal Diffuse Large B-Cell Lymphoma Presenting as Laryngeal Stenosis.

Authors:  Yaoyun Tang; Peng Li; David Cua; Jinping Lai
Journal:  In Vivo       Date:  2020 Jan-Feb       Impact factor: 2.155

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.